Chapter 2 Urinary Markers in Colorectal Cancer

Advances in Clinical Chemistry

Volumn 47, Issue , 2009, Pages 45-57

  Feng, Bo ^a   Yue, Fei ^a   Zheng, Min Hua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

COLORECTAL TUMOR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE; REVIEW; URINE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; HUMANS; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 67651252158     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(09)47002-1     Document Type: Review

References (59)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 2 (2005) 74-108
2. You W.C., Jin F., Devesa S., et al. Rapid increase in colorectal cancer rates in urban Shanghai, 1972-1997, in relation to dietary changes. J. Cancer Epidemiol. Prev. 7 3 (2002) 143-146
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 57 1 (2007) 43-66
4. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16 3 (2005) 481-488
5. Bembenek A., Gretschel S., and Schlag P.M. Sentinel lymph node biopsy for gastrointestinal cancers. J. Surg. Oncol. 96 4 (2007) 342-352
6. Hewitson P., Glasziou P., Irwig L., Towler B., and Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst. Rev. (Online) 1 (2007) CD001216
7. Ballinger A.B., and Anggiansah C. Colorectal cancer. BMJ 335 7622 (2007) 715-718 (Clinical research ed.)
8. Booth R.A. Minimally invasive for detection and staging of colorectal cancer. Cancer Lett. 249 1 (2007) 87-96
9. Rochfort S. Metabolomics reviewed: a new "omics" platform technology for systems biology and implications for natural products research. J. Nat. Prod. 68 12 (2005) 1813-1820
10. Schroy III P.C., and Heeren T.C. Patient perceptions of stool-based DNA testing for colorectal cancer screening. Am. J. Prev. Med. 28 2 (2005) 208-214
11. Brand R.E., Ross M.E., and Shuber A.P. Reproducibility of a multitarget stool-based DNA assay for colorectal cancer detection. Am. J. Gastroenterol. 99 7 (2004) 1338-1341
12. Duffy M.J., van Dalen A., Haglund C., Hansson L., Klapdor R., Lamerz R., Nilsson O., Sturgeon C., and Topolcan O. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur. J. Cancer 39 6 (2003) 718-727
13. Holten-Andersen M.N., Fenger C., Nielsen H.J., Rasmussen A.S., Christensen I.J., Brünner N., and Kronborg O. Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. Eur. J. Cancer 40 14 (2004) 2159-2164
14. Thongboonkerd V. Practical points in urinary proteomics. J. Prot. Res. 6 10 (2007) 3881-3890
15. Theodorescu D., and Mischak H. Mass spectrometry based proteomics in urine biomarker discovery. World J. Urol. 25 5 (2007) 435-443
16. Muller H., and Brenner H. Urine markers as possible tools for prostate cancer screening: review of performance characteristics and practicality. Clin. Chem. 52 4 (2006) 562-573
17. M'Koma A.E., Blum D.L., Norris J.L., Koyama T., Billheimer D., Motley S., Ghiassi M., Ferdowsi N., Bhowmick I., Chang S.S., Fowke J.H., Caprioli R.M., and Bhowmick N.A. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem. Biophys. Res. Commun. 353 3 (2007) 829-834
18. Theodorescu D., Wittke S., Ross M.M., Walden M., Conaway M., Just I., Mischak H., and Frierson H.F. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 7 3 (2006) 230-240
19. Xu G., Schmid H.R., Lu X., Liebich H.M., and Lu P. Excretion pattern investigation of urinary normal and modified nucleosides of breast cancer patients by RP-HPLC and factor analysis method. Biomed. Chromatogr. 14 7 (2000) 459-463
20. Zheng Y.F., Xu G.W., Liu D.Y., Xiong J.H., Zhang P.D., Zhang C., Yang Q., and Lv S. Study of urinary nucleosides as biological marker in cancer patients analyzed by micellar electrokinetic capillary chromatography. Electrophoresis 23 24 (2002) 4104-4109
21. Liebich H.M., Lehmann R., Xu G., Wahl H.G., and Haring H.U. Application of capillary electrophoresis in clinical chemistry: the clinical value of urinary modified nucleosides. J. Chromatogr. 745 1 (2000) 189-196
22. Mandel L.R., Srinivasan P.R., and Borek E. Origin of urinary methylated purines. Nature 209 5023 (1966) 586-588
23. Feng B., Zheng M.H., Zheng Y.F., Lu A.G., Li J.W., Wang M.L., Ma J.J., Xu G.W., Liu B.Y., and Zhu Z.G. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring. J. Gastroenterol. Hepatol. 20 12 (2005) 1913-1919
24. Hiramatsu K., Takahashi K., Yamaguchi T., Matsumoto H., Miyamoto H., Tanaka S., Tanaka C., Tamamori Y., Imajo M., Kawaguchi M., Toi M., Mori T., and Kawakita M. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clin. Cancer Res. 11 8 (2005) 2986-2990
25. 12-diacetylspermine as indicators of neoplastic diseases. J. Cancer Res. Clin. Oncol. 121 5 (1995) 317-319
26. 12-diacetylspermine in urine as novel markers of malignancy. J. Cancer Res. Clin. Oncol. 123 10 (1997) 539-545
27. 12-diacetylspermine in human urine. J. Biochem. 124 1 (1998) 231-236
28. Brown J.R., and DuBois R.N. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23 12 (2005) 2840-2855
29. Gupta R.A., and Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. 1 1 (2001) 11-21
30. Wendum D., Masliah J., Trugnan G., and Flejou J.F. Cyclooxygenase-2 and its role in colorectal cancer development. Virch. Arch. 445 4 (2004) 327-333
31. Cai Q., Gao Y.T., Chow W.H., Shu X.O., Yang G., Ji B.T., Wen W., Rothman N., Li H.L., Morrow J.D., and Zheng W. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J. Clin. Oncol. 24 31 (2006) 5010-5016
32. Murphey L.J., Williams M.K., Sanchez S.C., Byrne L.M., Csiki I., Oates J.A., and Johnson D.H. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal. Biochem. 334 2 (2004) 266-275
33. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 4 (1994) 1183-1188
34. Elder D.J., Baker J.A., Banu N.A., Moorghen M., and Paraskeva C. Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J. Pathol. 198 4 (2002) 428-434
35. Hao X., Bishop A.E., Wallace M., Wang H., Willcocks T.C., Maclouf J., Polak J.M., Knight S., and Talbot I.C. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J. Pathol. 187 3 (1999) 295-301
36. Yuan J.M., Gao Y.T., Yang C.S., and Yu M.C. Urinary biomarkers of tea polyphenols and risk of colorectal cancer in the Shanghai Cohort Study. Intl. J. Cancer 120 6 (2007) 1344-1350
37. Yin P., Zhao J., Cheng S., Zhu Q., Liu Z., and Zhengguo L. Experimental studies of the inhibitory effects of green tea catechin on mice large intestinal cancers induced by 1,2-dimethylhydrazine. Cancer Lett. 79 1 (1994) 33-38
38. Xu M., Bailey A.C., Hernaez J.F., Taoka C.R., Schut H.A., and Dashwood R.H. Protection by green tea, black tea, and indole-3-carbinol against 2-amino-3-methylimidazo[4,5-f]quinoline-induced DNA adducts and colonic aberrant crypts in the F344 rat. Carcinogenesis 17 7 (1996) 1429-1434
39. Yang C.S., Maliakal P., and Meng X. Inhibition of carcinogenesis by tea. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 25-54
40. Ju J., Hong J., Zhou J.N., et al. Inhibition of intestinal tumorigenesis in Apcmin/+mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res. 65 22 (2005) 10623-10631
41. Jin F., Devesa S.S., Zheng W., Blot W.J., Fraumeni Jr. J.F., and Gao Y.T. Cancer incidence trends in urban Shanghai, 1972-1989. Int. J. Cancer 53 5 (1993) 764-770
42. Norat T., and Riboli E. Meat consumption and colorectal cancer: a review of epidemiologic evidence. Nutr. Rev. 59 2 (2001) 37-47
43. Alary J., Bravais F., Cravedi J.P., Debrauwer L., Rao D., and Bories G. Mercapturic acid conjugates as urinary end metabolites of the lipid peroxidation product 4-hydroxy-2-nonenal in the rat. Chem. Res. Toxicol. 8 1 (1995) 34-39
44. Peiro G., Alary J., Cravedi J.P., Rathahao E., Steghens J.P., and Gueraud F. Dihydroxynonene mercapturic acid, a urinary metabolite of 4-hydroxynonenal, as a biomarker of lipid peroxidation. BioFactors (Oxford, England) 24 1-4 (2005) 89-96
45. Pierre F., Peiro G., Tache S., Cross A.J., Bingham S.A., Gasc N., Gottardi G., Corpet D.E., and Guéraud F. New marker of colon cancer risk associated with heme intake: 1,4-dihydroxynonane mercapturic acid. Cancer Epidemiol. Biomarkers Prev. 15 11 (2006) 2274-2279
46. Lindon J.C., Holmes E., Bollard M.E., Stanley E.G., and Nicholson J.K. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 9 1 (2004) 1-31
47. 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J. Pharm. Biomed. Anal. 33 5 (2003) 1103-1115
48. Bollard M.E., Stanley E.G., Lindon J.C., Nicholson J.K., and Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed. 18 3 (2005) 143-162
49. 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J. Pharm. Biomed. Anal. 36 4 (2004) 841-849
50. 13C HMBC-NMR spectroscopy combined with pattern recognition procedures performed on filtered variables. Anal. Chem. 74 10 (2002) 2261-2273
51. Viant M.R. Improved methods for the acquisition and interpretation of NMR metabolomic data. Biochem. Biophys. Res. Commun. 310 3 (2003) 943-948
52. Dekker L.J., Burgers P.C., Guzel C., and Luider T.M. FTMS and TOF/TOF mass spectrometry in concert: identifying peptides with high reliability using matrix prespotted MALDI target plates. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 847 1 (2007) 62-64
53. Meng F., Wiener M.C., Sachs J.R., Burns C., Verma P., Paweletz C.P., Mazur M.T., Deyanova E.G., Yates N.A., and Hendrickson R.C. Quantitative analysis of complex peptide mixtures using FTMS and differential mass spectrometry. J. Am. Soc. Mass Spectrom. 18 2 (2007) 226-233
54. Hoh C., Boocock D., Marczylo T., Singh R., Berry D.P., Dennison A.R., Hemingway D., Miller A., West K., Euden S., Garcea G., Farmer P.B., Steward W.P., and Gescher A.J. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin. Cancer Res. 12 9 (2006) 2944-2950
55. Van Q.N., Klose J.R., Lucas D.A., Prieto D.A., Luke B., Collins J., Burt S.K., Chmurny G.N., Issaq H.J., Conrads T.P., Veenstra T.D., and Keay S.K. The use of urine proteomic and metabonomic patterns for the diagnosis of interstitial cystitis and bacterial cystitis. Dis. Markers 19 4-5 (2003) 169-183
56. Toyoda T., and Wada A. Omic space: coordinate-based integration and analysis of genomic phenomic interactions. Bioinformatics (Oxford, England) 20 11 (2004) 1759-1765
57. 1H-NMR-based metabonomics. Nat. Med. 8 12 (2002) 1439-1444
58. Pisitkun T., Johnstone R., and Knepper M.A. Discovery of urinary biomarkers. Mol. Cell Proteomics 5 10 (2006) 1760-1771
59. Lindon J.C., Nicholson J.K., Holmes E., et al. Summary recommendations for standardization and reporting of metabolic analyses. Nat. Biotechnol. 23 7 (2005) 833-838